KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Current Taxes (2022 - 2024)

Acadia Pharmaceuticals has reported Current Taxes over the past 3 years, most recently at $8.5 million for Q2 2024.

  • Quarterly results put Current Taxes at $8.5 million for Q2 2024, changed N/A from a year ago — trailing twelve months through Jun 2024 was $8.5 million (changed N/A YoY), and the annual figure for FY2023 was $8.7 million, up 2210.34%.
  • Current Taxes for Q2 2024 was $8.5 million at Acadia Pharmaceuticals, up from $7.6 million in the prior quarter.
  • Over the last five years, Current Taxes for ACAD hit a ceiling of $8.7 million in Q4 2023 and a floor of $377000.0 in Q4 2022.
  • Median Current Taxes over the past 3 years was $8.5 million (2023), compared with a mean of $6.7 million.
  • Peak annual rise in Current Taxes hit 2210.34% in 2023, while the deepest fall reached 2210.34% in 2023.
  • Acadia Pharmaceuticals' Current Taxes stood at $377000.0 in 2022, then skyrocketed by 2210.34% to $8.7 million in 2023, then decreased by 2.92% to $8.5 million in 2024.
  • The last three reported values for Current Taxes were $8.5 million (Q2 2024), $7.6 million (Q1 2024), and $8.7 million (Q4 2023) per Business Quant data.